Symbols

PTGX

Protagonist·NASDAQ

--(--)

PTGX Profile

Protagonist Therapeutics, Inc.

A biopharmaceutical company that developing peptide-based new chemical entities for the treatment of inflammatory bowel disease

Industry

Pharmaceutical

Established Date

08/22/2006

Listing Date

08/11/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

132

Fiscal Year Ends

12-31

Website

www.protagonist-inc.com

Security Type

Common stock

Office address

7707 Gateway Boulevard, Suite 140, Newark, California 94560

Business

Introduction

Protagonist Therapeutics, Inc., incorporated in Delaware on August 22, 2006, is headquartered in Milpitas, California. The company is a biopharmaceutical company, and its new peptide-based chemical entities rusfertide and JNJ-2113 (formerly PN-235) are in different stages of development, both derived from proprietary discovery technology platforms. The company's clinical programs are divided into two categories of diseases: (i) hematological and hematological diseases, and (ii) inflammatory and immunomodulatory diseases.